NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$5.0b

Last Updated

2021/04/10 10:33 UTC

Data Sources

Company Financials

Executive Summary

Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China. More Details


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Mabpharm's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2181 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 2181's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-0.8%

2181

-1.3%

HK Biotechs

-0.5%

HK Market


1 Year Return

30.1%

2181

63.8%

HK Biotechs

29.2%

HK Market

Return vs Industry: 2181 underperformed the Hong Kong Biotechs industry which returned 63.8% over the past year.

Return vs Market: 2181 matched the Hong Kong Market which returned 29.2% over the past year.


Shareholder returns

2181IndustryMarket
7 Day-0.8%-1.3%-0.5%
30 Day1.7%14.8%2.3%
90 Day28.7%9.0%4.0%
1 Year30.1%30.1%64.1%63.8%34.2%29.2%
3 Yearn/a-35.5%-36.7%4.2%-6.8%
5 Yearn/a-1.3%-5.0%48.8%23.7%

Long-Term Price Volatility Vs. Market

How volatile is Mabpharm's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mabpharm undervalued compared to its fair value and its price relative to the market?

4.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2181's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2181's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2181 is unprofitable, so we can't compare its PE Ratio to the HK Biotechs industry average.

PE vs Market: 2181 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2181's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2181 is overvalued based on its PB Ratio (4.8x) compared to the HK Biotechs industry average (3.4x).


Future Growth

How is Mabpharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

57.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mabpharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Mabpharm performed over the past 5 years?

8.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 2181 is currently unprofitable.

Growing Profit Margin: 2181 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2181's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2181's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2181 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.5%).


Return on Equity

High ROE: 2181 has a negative Return on Equity (-20.95%), as it is currently unprofitable.


Financial Health

How is Mabpharm's financial position?


Financial Position Analysis

Short Term Liabilities: 2181's short term assets (CN¥569.1M) exceed its short term liabilities (CN¥202.6M).

Long Term Liabilities: 2181's short term assets (CN¥569.1M) exceed its long term liabilities (CN¥78.9M).


Debt to Equity History and Analysis

Debt Level: 2181's debt to equity ratio (0%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 2181's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 2181 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2181 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Mabpharm current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2181's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2181's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2181's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2181's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2181's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Mabpharm has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Mabpharm Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mabpharm Limited
  • Ticker: 2181
  • Exchange: SEHK
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$4.990b
  • Shares outstanding: 4.12b
  • Website: https://www.mabpharm.cn

Number of Employees


Location

  • Mabpharm Limited
  • Block G79
  • Lujia Road East
  • Taizhou
  • Zhejiang Province
  • 225300
  • China

Listings


Biography

Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China. Its products under the Phase ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/10 10:33
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.